Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Erythropoietin

40,000 units injected under the skin (SQ) weekly

DRUG

Cyclosporin A

300 mg (tablets) by mouth daily for 6 months

DRUG

G-CSF

300 mcg injected under the skin (SQ) two times per week

DRUG

Prednisone

60 mg per day for 7 days, taper over 1 month

Trial Locations (1)

U.T.M.D. Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER

NCT00520468 - Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS | Biotech Hunter | Biotech Hunter